A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan

PHASE2CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

December 31, 2007

Conditions
Periodontitis
Interventions
DRUG

Trafermin (genetical recombination)

Trial Locations (23)

464-8651

Kaken Investigational Site, Nagoya

261-0011

Kaken Investigational Site, Chiba

271-8587

Kaken Investigational Site, Matsudo

812-8582

Kaken Investigational Site, Fukuoka

814-0193

Kaken Investigational Site, Fukuoka

803-8580

Kaken Investigational Site, Kitakyushu

501-0296

Kaken Investigational Site, Mizuho

734-8551

Kaken Investigational Site, Hiroshima

061-0293

Kaken Investigational Site, Ishikari-gun

060-8648

Kaken Investigational Site, Sapporo

020-8505

Kaken Investigational Site, Morioka

890-8520

Kaken Investigational Site, Kagoshima

230-8501

Kaken Investigational Site, Yokohama

980-8575

Kaken Investigational Site, Sendai

852-8501

Kaken Investigational Site, Nagasaki

951-8122

Kaken Investigational Site, Niigata

700-8525

Kaken Investigational Site, Okayama

565-0871

Kaken Investigational Site, Suita

770-8503

Kaken Investigational Site, Tokushima

113-8549

Kaken Investigational Site, Bunkyo-ku

101-8310

Kaken Investigational Site, Chiyoda-ku

194-0023

Kaken Investigational Site, Machida

160-8582

Kaken Investigational Site, Sinjyuku-ku

Sponsors
All Listed Sponsors
lead

Kaken Pharmaceutical

INDUSTRY